Verve Therapeutics
Price & Volume
Stats
See moreOpen | $5.24 |
Previous Close | $5.28 |
Day Range | $5.18-$5.37 |
52W Range | $4.30-$13.24 |
Market Cap | $468.8M |
Shares Short | 14M |
Financials
See moreRevenue (12 Mos) | $32.3M |
Revenue Growth (YoY) | 154.3% |
Gross Profit (12 Mos) | $9.4M |
Diluted EPS | -$2.35 |
News
See moreYahoo Finance • 5 days ago
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
Yahoo Finance • 26 days ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance • 2 months ago
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Yahoo Finance • 6 months ago
Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?
About
CEO | Dr. Sekar Kathiresan M.D. |
CFO | Ms. Allison Dorval CPA |
Address | 201 Brookline Avenue, Boston, MA, United States, 02215 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 274 |
